These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 11344833

  • 1. Homocysteine elevation with fibrates: is it a class effect?
    Harats D, Yodfat O, Doolman R, Gavendo S, Marko D, Shaish A, Sela BA.
    Isr Med Assoc J; 2001 Apr; 3(4):243-6. PubMed ID: 11344833
    [Abstract] [Full Text] [Related]

  • 2. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.
    Dierkes J, Westphal S, Luley C.
    Expert Opin Drug Saf; 2004 Mar; 3(2):101-11. PubMed ID: 15006716
    [Abstract] [Full Text] [Related]

  • 3. Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.
    Melenovsky V, Stulc T, Kozich V, Grauova B, Krijt J, Wichterle D, Haas T, Malik J, Hradec J, Ceska R.
    Am Heart J; 2003 Jul; 146(1):110. PubMed ID: 12851616
    [Abstract] [Full Text] [Related]

  • 4. Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia.
    de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C.
    Thromb Haemost; 1997 Jan; 77(1):75-9. PubMed ID: 9031453
    [Abstract] [Full Text] [Related]

  • 5. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V, Souki A, Cano-Ponce C, Bermúdez-Arias F, Mengual-Moreno E, Leal-Gonzalez E, Lemus-Antepaz M, de Bravo MC, de Díaz AA, de Pirela NL, Cano-Peñaloza R, Puche-Medina G, Arraiz N, Reyna-Villazmil N, Contreras F, Israili ZH, Valasco M.
    Am J Ther; 2007 Jan; 14(2):213-20. PubMed ID: 17414592
    [Abstract] [Full Text] [Related]

  • 6. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
    Kockx M, de Maat MP, Knipscheer HC, Kastelein JJ, Kluft C, Princen HM, Kooistra T.
    Thromb Haemost; 1997 Oct; 78(4):1167-72. PubMed ID: 9364979
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
    Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES.
    J Am Coll Cardiol; 2005 Jan 18; 45(2):185-97. PubMed ID: 15653014
    [Abstract] [Full Text] [Related]

  • 8. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.
    Visnegarwala F, Maldonado M, Sajja P, Minihan JL, Rodriguez-Barradas MC, Ong O, Lahart CJ, Hasan MQ, Balasubramanyam A, White AC.
    J Infect; 2004 Nov 18; 49(4):283-90. PubMed ID: 15474625
    [Abstract] [Full Text] [Related]

  • 9. N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination.
    Zeman M, Zák A, Vecka M, Tvrzická E, Písaríková A, Stanková B.
    J Nutr Biochem; 2006 Jun 18; 17(6):379-84. PubMed ID: 16214329
    [Abstract] [Full Text] [Related]

  • 10. Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.
    Hernández C, Lecube A, Barberá G, Chacón P, Lima J, Simó R.
    Med Sci Monit; 2003 Mar 18; 9(3):CR114-9. PubMed ID: 12640339
    [Abstract] [Full Text] [Related]

  • 11. Ciprofibrate--a profile.
    Betteridge DJ.
    Postgrad Med J; 1993 Mar 18; 69 Suppl 1():S42-7; discussion S47-9. PubMed ID: 8497456
    [Abstract] [Full Text] [Related]

  • 12. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
    Cenarro A, Artieda M, Gonzalvo C, Meriño-Ibarra E, Arístegui R, Gañán A, Díaz C, Sol JM, Pocoví M, Civeira F, ATOMIX Study Group.
    Am Heart J; 2005 Dec 18; 150(6):1154-62. PubMed ID: 16338252
    [Abstract] [Full Text] [Related]

  • 13. [Therapeutic effects of bezafibrate in hyperlipidemia].
    Kunesová M, Honková M, Zeman M, Mares P, Skorepa J.
    Cas Lek Cesk; 1983 May 20; 122(20):628-31. PubMed ID: 6342789
    [No Abstract] [Full Text] [Related]

  • 14. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA.
    Br J Clin Pract Suppl; 1994 Dec 20; (77):28-32. PubMed ID: 19496270
    [Abstract] [Full Text] [Related]

  • 15. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.
    Metabolism; 2005 May 20; 54(5):677-81. PubMed ID: 15877299
    [Abstract] [Full Text] [Related]

  • 16. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P, Scheuermann E, Lang W.
    Proc Eur Dial Transplant Assoc; 1981 May 20; 18():169-75. PubMed ID: 7036147
    [Abstract] [Full Text] [Related]

  • 17. [Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates].
    Zeman M, Zák A, Vecka M, Romaniv S.
    Cas Lek Cesk; 2003 Aug 20; 142(8):500-4. PubMed ID: 14626567
    [Abstract] [Full Text] [Related]

  • 18. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Naruszewicz M, Nowicka G, Szostak WB, Kłosiewicz-Latoszek L.
    Kardiol Pol; 1982 Aug 20; 25(7-8):527-31. PubMed ID: 7169740
    [No Abstract] [Full Text] [Related]

  • 19. Bezafibrate and lovastatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlidemia.
    Zambrana JL, López-Miranda J, Blanco A, Arizón JM, Jansen S, Paniagua JA, Jimenéz-Perepérez JA, Concha M, Pérez-Jiménez F.
    J Heart Lung Transplant; 1998 Dec 20; 17(12):1213-9. PubMed ID: 9883763
    [Abstract] [Full Text] [Related]

  • 20. Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
    Papadakis JA, Ganotakis ES, Jagroop IA, Winder AF, Mikhailidis DP.
    Int J Cardiol; 1999 Jun 01; 69(3):237-44. PubMed ID: 10402106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.